

Docket No. AB-145U

Amendments to and Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A method of preventing diabetes or treating patients with diabetes, comprising:

implanting at least one system control unit in at least one of the skull and the brain of the patient, wherein the at least one unit controls the delivery of at least one stimulus to at least one area of the brain affecting diabetes;

applying the at least one stimulus to the at least one area of the brain that exhibits chronic abnormal activity, in order to prevent or treat diabetes,

wherein the area is selected from at least one of the dorsal motor nucleus of the vagus nerve, and the nucleus of the solitary tract.

Claim 2 (original): The method of Claim 1 wherein the at least one system control unit is connected to at least two electrodes, and wherein the stimulus comprises electrical stimulation delivered via the at least two electrodes.

Claim 3 (original): The method of Claim 1 wherein the at least one system control unit is connected to at least one pump and at least one infusion outlet, and wherein the stimulus comprises stimulation via one or more drugs delivered from the at least one pump through the at least one outlet.

Claims 4 -14 (canceled)

Claim 15 (original): The method of Claim 1 wherein the stimulus is at least one stimulating drug.

Claim 16 (original): The method of Claim 1 wherein the stimulus is electrical stimulation.

Appl. Ser. No. 09/993,085
Amendment dated November 2, 2004
Reply to final Office action of July 2, 2004

Page 2 of 13

Docket No. AB-145U

Claim 17 (original): The method of Claim 1 wherein the stimulus is electrical stimulation and at least one stimulating drug.

Claim 18 (original): The method of Claim 1 further comprising applying the stimulus in coordination with delivery of a medication.

Claim 19 (original): The method of Claim 1 further comprising sensing at least one condition and using the at least one sensed condition to automatically determine the stimulus to apply.

Claim 20 (original): The method of Claim 1 further comprising implanting more than one system control unit.

Claim 21 (original): The method of Claim 1 wherein implanting at least one system control unit comprises implanting at least one microstimulator.

Claim 22 (currently amended): A method of preventing metabolic disorders or treating patients with metabolic disorders, comprising:

implanting at least one system control unit in at least one of the skull and the brain of the patient, wherein the at least one unit controls the delivery of at least one stimulus to at least one area of the brain affecting a metabolic disorder;

applying the at least one stimulus to the at least one area of the brain that exhibits chronic abnormal activity, in order to prevent or treat the metabolic disorder,

wherein the area is selected from at least one of the dorsal motor nucleus of the vagus nerve, and the nucleus of the solitary tract.

Claim 23 (previously presented): The method of Claim 22, further comprising:

sensing at least one condition indicating a need for said at least one stimulus in order to treat or prevent metabolic disorder;

Appl. Ser. No. 09/993,085
Amendment dated November 2, 2004
Reply to final Office action of July 2, 2004

Page 3 of 13

Docket No. AB-145U

wherein the at least one sensed condition is at least one of electrical activity of the brain, nerve activity, muscle activity, body mass, impedance, pH, neurotransmitter level, neurotransmitter breakdown product level, hormone level, ketone level, glucose level, electrolyte level, enzyme level, cytokine level, medication level, other drug level, and level of any other bloodborne substance.

Claim 24 (previously presented): The method of Claim 23 wherein the at least one sensed condition is the level of one or more of Neuropeptide Y (NPY), serotonin, one or more catecholamines, adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), growth hormone (GH), thyroid stimulating hormone (TSH), leptin, ghrelin, AGRP, orexin-A, orexin-B, cholecystokinin (CCK), glucagon, and glucocorticoids.

Claim 25 (previously presented): The method of Claim 23 wherein the at least one system control unit is configured to use the sensed condition to control the delivery of the at least one stimulus.

Claim 26 (previously presented): The method of Claim 22 wherein implanting the at least one system control unit further comprises:

implanting at least one pump, the pump having:
at least one infusion outlet; and
fluid connections connecting the at least one pump to the at least one infusion outlet; and

wherein the at least one stimulus is at least one stimulating drug delivered to the at least one area of the brain in order to treat or prevent metabolic disorders.

Claim 27 (currently amended): The method of Claim 26 wherein the at least one pump and the at least one infusion outlet are further configured to deliver a liquid that increases excitement of the at least one area of the brain that exhibits chronic decreased activity; and

wherein the at least one area of the brain is at least one of the nucleus of the solitary tract, and the dorsal motor nucleus of the vagus nerve.

Docket No. AB-145U

Claim 28 (previously presented): The method of Claim 27 wherein the at least one pump and the at least one infusion outlet are further configured to deliver at least one of an excitatory neurotransmitter agonist, a medication that increases levels of at least one excitatory neurotransmitter, an excitatory hormone agonist, an inhibitory neurotransmitter antagonist, an inhibitory hormone antagonist, corticotropin releasing factor, a corticotropin releasing factor agonist, bombesin, a bombesin agonist, glucagon-like peptide 1, a glucagon-like peptide 1 agonist, serotonin, a serotonin agonist, leptin, a leptin agonist, a ghrelin antagonist, an AGRP antagonist, an MC4-R agonist, an MC3-R agonist, an orexin-A antagonist, an orexin-B antagonist, an OX1R antagonist, an OX2R antagonist, cholecystokinin, and a cholecystokinin agonist.

Claim 29 (previously presented): The method of Claim 28 wherein the at least one pump and the at least one infusion outlet are further configured to deliver a liquid that decreases excitement of the at least one area of the brain that exhibits chronic increased activity.

Claim 30 (previously presented): The method of Claim 29 wherein the at least one pump and the at least one infusion outlet are further configured to deliver at least one of an inhibitory neurotransmitter agonist, a medication that increases the level of an inhibitory neurotransmitter, an inhibitory hormone agonist, an excitatory neurotransmitter antagonist, and/or an excitatory hormone antagonist.

Claim 31 (previously presented): The method of Claim 22 wherein implanting the at least one system control unit further comprises:

implanting at least two electrodes configured to apply electrical stimulation to the at least one area of the brain in order to prevent or treat metabolic disorders; and

connecting the at least one system control unit to the at least two electrodes, through which the electrical stimulation is delivered to the at least one area adjacent to the electrodes.

Docket No. AB-145U

Claim 32 (currently amended): The method of Claim 31 wherein the at least one system control unit is further configured to control the delivery of electrical stimulation pulses at less than about 100 to 150 Hz; and

wherein the at least one area of the brain is ~~at least one of the nucleus of the solitary tract, and the dorsal motor nucleus of the vagus nerve.~~

Claim 33 (previously presented): The method of Claim 31 wherein the at least one system control unit is further configured to control the delivery of electrical stimulation pulses at greater than about 100 to 150 Hz.

Claim 34 (previously presented): The method of Claim 22 wherein the at least one system control unit is configured to conform to the profile of the skull.

Claim 35 (previously presented): The method of Claim 22 wherein the at least one system control unit is at least one microstimulator.

Appl. Ser. No. 09/993,085
Amendment dated November 2, 2004
Reply to final Office action of July 2, 2004

Page 6 of 13

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.